Stay updated with breaking news from Jay Feingold. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ZYNLONTA LOTIS-2 updated data includes median duration of response of 13.4 months in heavily pre-treated patients with relapsed or refractory DLBCL Subgroup analyses include patients with double-
(1) Camidanlumab tesirine (Cami) demonstrated anti-tumoral activity response rate in 86% of Hodgkin lymphoma patients at dose currently being evaluated in ongoing pivotal Phase 2 trial ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced that results of the Phase 1 clinical trial of camidanlumab tesirine (Cami), an anti-CD25 ADC, in patients with relapsed or refractory Hodgkin and non-Hodgkin lymphomas have been published online in The La...
Published: May 12, 2021 ZYNLONTA™ demonstrated substantial single-agent activity, durable responses and an acceptable safety profile in broad population of difficult-to-treat patients with relapsed or refractory DLBCL LAUSANNE, Switzerland--(BUSINESS WIRE)-- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced that results of LOTIS-2, a multicenter, open-label, single-arm Phase 2 clinical trial evaluating the safety and effic...
Recent FDA approval of ZYNLONTA™ (loncastuximab tesirine-lpyl) was based on data from LOTIS-2ZYNLONTA™ demonstrated substantial single-agent activity, durable responses and an acceptable safety profile in broad population of difficult-to-treat patients with relapsed or refractory DLBCLLAUSANNE, Switzerland--(BUSINES...
ADC Therapeutics SA: ADC Therapeutics Announces Online Publication of LOTIS-2 Results in The Lancet Oncology ZYNLONTA demonstrated substantial single-agent activity, durable responses and an acceptable safety profile in broad population of difficult-to-treat patients with relapsed or refractory DLBCL ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced that results of LOTIS-2, a multicenter, open-label, single-arm Phase 2 clinical trial ...